MedTrace Logo

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

NCT05404906 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2022-08-19

No results posted yet for this study

Summary

This phase III trial is conducted to evaluate if azacitidine in combination with venetoclax as maintenance therapy improves relapse-free survival (RFS) for younger adults with favorable-risk acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive consolidation.

Conditions

  • Acute Myeloid Leukemia (AML) in Remission

Interventions

DRUG

Azacitidine

Given SC

DRUG

Venetoclax

Given PO

OTHER

Supportive care

Patients will receive disease monitoring and supportive care for any complication.

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Suning Chen · First Affiliated Hospital of Soochow University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-25
Primary Completion
2028-06-30
Completion
2030-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05404906 on ClinicalTrials.gov